Intermittent Lu-177-PSMA-617 therapy of metastatic castration-resistant prostate cancer in early responders

被引:0
|
作者
Mader, Nicolai [1 ]
Ngoc, Christina Nguyen [1 ]
Baumgarten, Justus [1 ]
Groener, Daniel [1 ]
Davis, Karen [1 ]
Wichert, Jennifer
Tselis, Nikolaos [2 ]
Mandel, Philipp [3 ]
Gruenwald, Frank [1 ]
Sabet, Amir [1 ]
机构
[1] Univ Hosp Frankfurt, Nucl Med, Frankfurt, Germany
[2] Univ Hosp Frankfurt, Radiooncol, Frankfurt, Germany
[3] Univ Hosp Frankfurt, Urol, Frankfurt, Germany
关键词
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
1271
引用
收藏
页数:2
相关论文
共 50 条
  • [31] 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney
    Zhang, Jingjing
    Kulkarni, Harshad R.
    Singh, Aviral
    Schuchardt, Christiane
    Niepsch, Karin
    Langbein, Thomas
    Baum, Richard P.
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (11) : 1579 - 1586
  • [32] Radiobiological parameters for the assessment of 177Lu-PSMA-617 Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
    Hu, J.
    Xue, S.
    Mercolli, L.
    Sari, H.
    Rominger, A.
    Afshar-Oromieh, A.
    Shi, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S636 - S636
  • [33] Safety and dosimetry of 177Lu-EB-PSMA617 in patients with metastatic castration-resistant prostate cancer
    Zang, Jie
    Wang, Hao
    Liu, Qingxing
    Jacobson, Orit
    Niu, Gang
    Zhu, Zhaohui
    Chen, Xiaoyuan
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [34] 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney
    Zhang, Jingjing
    Kulkarni, Harshad
    Singh, Aviral
    Schuchardt, Christiane
    Niepsch, Karin
    Langbein, Thomas
    Baum, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [35] Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer
    Mehrens, Dirk
    Kramer, Kristina K. M.
    Unterrainer, Lena M.
    Beyer, Leonie
    Bartenstein, Peter
    Froelich, Matthias F.
    Tollens, Fabian
    Ricke, Jens
    Ruebenthaler, Johannes
    Schmidt-Hegemann, Nina-Sophie
    Herlemann, Annika
    Unterrainer, Marcus
    Kunz, Wolfgang G.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2023, 21 (01): : 43 - +
  • [36] PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under 177Lu-PSMA-617 Radioligand Therapy
    Widjaja, Liam
    Werner, Rudolf A.
    Ross, Tobias L.
    Bengel, Frank M.
    Derlin, Thorsten
    CANCERS, 2021, 13 (12)
  • [37] Personalized dosimetry assessment of [177Lu]Lu-PSMA-617 radioligand therapy in the management of metastatic castration-resistant prostate cancer
    Kazemi-Jahromi, Mahmood
    Yazdani, Elmira
    Karamzade-Ziarati, Najme
    Asadi, Mahboobeh
    Sadeghi, Mahdi
    Geramifar, Parham
    INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2024, 100 (11) : 1551 - 1559
  • [38] Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
    Hadaschik, Boris
    Herrmann, Ken
    EUROPEAN UROLOGY, 2021, 80 (04) : 520 - 521
  • [39] Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
    Sartor, O.
    de Bono, J.
    Chi, K. N.
    Fizazi, K.
    Herrmann, K.
    Rahbar, K.
    Tagawa, S. T.
    Nordquist, L. T.
    Vaishampayan, N.
    El-Haddad, G.
    Park, C. H.
    Beer, T. M.
    Armour, A.
    Perez-Contreras, W. J.
    DeSilvio, M.
    Kpamegan, E.
    Gericke, G.
    Messmann, R. A.
    Morris, M. J.
    Krause, B. J.
    JOURNAL OF UROLOGY, 2022, 207 (02): : 467 - 468
  • [40] 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
    Axel Bräuer
    Lena Sophie Grubert
    Wolfgang Roll
    Andres Jan Schrader
    Michael Schäfers
    Martin Bögemann
    Kambiz Rahbar
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1663 - 1670